Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States.

Sang Hee ParkMark LambtonJordana K Schmier Sara Hovland Keith Wittstock Vardhaman Patel

Published in: The Journal of dermatological treatment (2024)

Scenario analyses found mainly consistent results. This study showed that the CPR is lower when initiating deucravacitinib versus apremilast in moderate to severe plaque psoriasis.

Keyphrases

coronary artery disease
high intensity
cardiac arrest
early onset
cardiopulmonary resuscitation
drug induced